Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News Feature
  • Published:

Worth the RISC?

Nature Biotechnology volume 35, pages 198–202 (2017)Cite this article

Subjects

The long, tortuous race to market a therapeutic based on RNA interference (RNAi) may be nearing its end. Ken Garber reports.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: siRNA therapies face many barriers to reaching their targets.

References

  1. Garber, K. Nat. Biotechnol. 34, 1213–1214 (2016)

    Article  CAS  Google Scholar 

  2. Elbashir, S.M. et al. Nature 411, 494–498 (2001).

    Article  CAS  Google Scholar 

  3. Zuckerman, J.E. et al. Proc. Natl. Acad. Sci. USA 111, 11449–11454 (2014).

    Article  CAS  Google Scholar 

  4. Tabernero, J. et al. Cancer Discov. 3, 406–417 (2013).

    Article  CAS  Google Scholar 

  5. Coelho, T. et al. N. Engl. J. Med. 369, 819–829 (2013).

    Article  CAS  Google Scholar 

  6. Nair, J.K. et al. J. Am. Chem. Soc. 136, 16958–16961 (2014).

    Article  CAS  Google Scholar 

  7. Fitzgerald, K. et al. N. Engl. J. Med. 376, 41–51 (2017).

    Article  CAS  Google Scholar 

  8. Grimm, D. et al. Nature 441, 537–541 (2006).

    Article  CAS  Google Scholar 

  9. Shen, W., Liang, X.H., Sun, H. & Crooke, S.T. Nucleic Acids Res. 43, 4569–4578 (2015).

    Article  CAS  Google Scholar 

  10. Janas, M.M. et al. Nucleic Acids Ther. doi:1089/nat.2016.0639 (2016).

  11. Pasi K.J. et al. Blood 128, 1397 (2016).

    Google Scholar 

  12. Ragni, M.V. Blood 128, 2572 (2016).

    Google Scholar 

  13. Sardh, E. et al. Blood 128, 2318 (2016).

    Google Scholar 

  14. Meade, B.R. et al. Nat. Biotechnol. 32, 1256–1261 (2014).

    Article  CAS  Google Scholar 

  15. Bartlett, D.W., Su, H., Hildebrandt, I.J., Weber, W.A. & Davis, M.E. Proc. Natl. Acad. Sci. USA 104, 15549–15554 (2007).

    Article  CAS  Google Scholar 

  16. Semple, S.C. et al. Nat. Biotechnol. 28, 172–176 (2010).

    Article  CAS  Google Scholar 

  17. Judge, A. & MacLachlan, I. Hum. Gene Ther. 19, 111–124 (2008).

    Article  CAS  Google Scholar 

  18. Barros, S.A. & Gollob, J.A. Adv. Drug Deliv. Rev. 64, 1730–1737 (2012).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ann Arbor, Michigan

    Ken Garber

Authors
  1. Ken Garber
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Garber, K. Worth the RISC?. Nat Biotechnol 35, 198–202 (2017). https://doi.org/10.1038/nbt.3810

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt.3810

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research